$ETSY

REIFF MELISSA sold $266K of ETSY

REIFF MELISSA sold 3,544 shares of ETSY INC (ETSY) at $75.00 ($0.27M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · REIFF MELISSA
Published Jun 18, 2026, 8:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ETSY
Neutral
high confidence
Mentioned
$ETSY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ETSYNeutralLow
01

Why it matters

A director’s open-market sale under a pre-arranged 10b5-1 plan is generally treated as routine compliance rather than a fundamental change signal.

02

Market read

Traders may note the sale for sentiment, but there is no new operational, guidance, or regulatory information to drive a decisive repricing.

03

What to watch

The disclosure does not indicate intent beyond the plan; without context on prior sales, total holdings, or whether the plan is part of a scheduled diversification, the signal is weak.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-18 after-hours; reflects sale executed 2026-06-17.

Background

The article is an SEC Form 4 insider transaction disclosure for Etsy, reported via SEC EDGAR.

Company-level read

Ticker impact

$ETSYNeutralHigh confidence
Context

SEC Form 4 shows director Melissa Reiff sold 3,544 shares of Etsy at $75.00 on 2026-06-17 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is an insider sale (not a purchase), explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

Minimal—this is company-specific insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of valuation or liquidity needs, which some traders may front-run.

Key entities

  • ETSY

    Etsy Inc., issuer of the Form 4 insider transaction.

  • Melissa Reiff

    Director who sold 3,544 shares of Etsy at $75.00/share on 2026-06-17 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WMTMed

Retailers Report AI-Driven Sales, Bigger Baskets in Q2 Earnings

Walmart, Amazon, and Target reported Q2 earnings showing AI-driven sales growth. Walmart's eCommerce grew 23%, with AI assistant users spending 40% more. Amazon's Alexa for Shopping saw active users nearly double. Target's digital traffic from AI platforms grew over 3.5x faster than the industry average. Albertsons saw a 10-26% increase in order value with AI tools. Shopify's AI-referred traffic and orders tripled, but AI's impact on discovery-driven retail remains uncertain.

$ETSYHigh

Bank of America Resets Etsy Stock Price Target After Event

Bank of America upgraded Etsy to Buy, raising its price target to $105 from $88, citing structural growth. The bank expects mid-single-digit gross merchandise sales growth, higher profitability, and increased shareholder returns. Etsy's new management team is seen as key to reinvigorating growth. BofA raised its fiscal 2027 estimates for gross merchandise sales, EBITDA, and EPS.

$DEMed

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.